Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients

Amino Acids. 2007 Jan;32(1):121-6. doi: 10.1007/s00726-006-0284-3. Epub 2006 Apr 20.

Abstract

The aim of this study was to evaluate the effect of pegylated interferon-alpha (PEG-IFN-alpha) on the plasma citrulline/arginine ratio, regarded as an index of nitric oxide (NO) synthesis, in patients with high-risk melanoma. Forty patients were randomly assigned to either PEG-IFN-alpha treatment (n = 22) or to observation only (control group, n = 18). The treatment group received 6 microg PEG-IFN-alpha/kg once a week during 8 weeks, followed by a maintenance dose of 3 microg/kg/wk. Blood was collected at different time points, plasma concentrations of citrulline and arginine were measured and the ratio of citrulline/arginine was calculated. Patients treated with PEG-IFN-alpha showed a significant decrease in the concentrations of citrulline and in the citrulline/arginine ratio during the whole study period, both compared to baseline values and to the control group. The data suggest that therapy with PEG-IFN-alpha results in a marked decrease in the synthesis of NO in melanoma patients.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / adverse effects
  • Arginine / blood*
  • Citrulline / blood*
  • Female
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Interferon-alpha / adverse effects
  • Male
  • Melanoma / blood*
  • Melanoma / therapy*
  • Nitric Oxide / biosynthesis
  • Polyethylene Glycols
  • Recombinant Proteins
  • Risk Factors
  • Time Factors

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Citrulline
  • Nitric Oxide
  • Polyethylene Glycols
  • Arginine
  • peginterferon alfa-2b